CYP1A2 rs7625511: Caffeine Metabolism and Trait Variation
The rs7625511 single nucleotide polymorphism is an intronic variant in the CYP1A2 gene, historically noted in research as CYP1A2*1F or -163C>A. It modulates the inducibility of the cytochrome P450 1A2 enzyme, which handles the vast majority of systemic caffeine clearance in humans. Epidemiological and physiological studies associate the variant with differences in caffeine clearance rates, habitual coffee consumption patterns, and cardiovascular responses such as blood pressure reactivity.
What each genotype means
Fast caffeine metabolizer
Individuals with this genotype are typically classified as fast metabolizers of caffeine due to higher enzyme inducibility. Research suggests that fast metabolizers may not experience the same increased risk of certain cardiovascular or kidney-related outcomes from heavy coffee intake as slow metabolizers. Please discuss any concerns regarding caffeine intake or medication dosing with your clinician or pharmacist.
This genotype is common globally, though frequencies vary significantly by continental ancestry.
Intermediate caffeine metabolizer
This genotype is associated with intermediate caffeine metabolism compared to the AA and CC variants. Some studies suggest that individuals with this genotype may exhibit slower caffeine clearance, which can influence sensitivity to caffeine's effects on blood pressure or kidney markers when coffee intake is high. Please discuss any concerns regarding caffeine intake or medication dosing with your clinician or pharmacist.
This is a very common heterozygous genotype found across most global populations.
Slow caffeine metabolizer
Individuals with this genotype are often classified as slow metabolizers of caffeine, as the C allele is associated with decreased CYP1A2 enzyme activity and inducibility. Some research indicates that heavy coffee consumption in slow metabolizers may be linked to an increased risk of hypertension or kidney dysfunction. Please discuss any concerns regarding caffeine intake or medication dosing with your clinician or pharmacist.
This genotype is common globally, with the C allele frequency ranging from approximately 30% to 45% depending on ancestry.
Genetic Architecture and Variant Location
The single nucleotide polymorphism rs7625511 sits within intron 1 of the CYP1A2 gene on chromosome 15 (specifically at 15q24). In academic literature, it is frequently described by its historical nomenclature, including CYP1A2*1F and c.-9-154C>A. Unlike coding mutations that alter the amino acid sequence of a protein directly, rs7625511 is a non-coding regulatory variant that influences gene transcription. Specifically, the variant modulates the degree to which CYP1A2 expression can be induced by external triggers, such as dietary factors, cigarette smoke, and substrate exposure. The presence of the ancestral C allele is characterized by lower baseline inducibility, whereas the derived A allele confers higher inducible promoter activity when exposed to environmental substrates.
Biological Function of the CYP1A2 Enzyme
The CYP1A2 gene encodes the cytochrome P450 family 1 subfamily A member 2 enzyme, a critical hepatic hemoprotein responsible for phase I xenobiotic biotransformation. As documented in biomedical literature, CYP1A2 accounts for roughly 95 percent of caffeine metabolism in the human liver, primary converting caffeine into paraxanthine, theobromine, and theophylline. Beyond caffeine, the enzyme participates in the clearance of several clinically important pharmaceuticals, including clozapine, theophylline, and tizanidine, as well as the metabolic activation of pro-carcinogens like heterocyclic aromatic amines. Because enzyme activity is heavily influenced by transcriptional induction via the aryl hydrocarbon receptor (AHR) pathway, variation within CYP1A2 regulatory regions directly alters the systemic clearance kinetics of its substrates.
Evidence on Caffeine Clearance and Cardiovascular Traits
Research across nutritional genomics associates rs7625511 with observable differences in caffeine pharmacokinetics and cardiovascular traits, though overall evidence remains limited and frequently nuanced. Individuals homozygous for the A allele typically exhibit faster systemic caffeine clearance and are designated as 'rapid metabolizers.' In contrast, carriers of the C allele (CA and CC genotypes) demonstrate slower elimination rates. Some epidemiological studies have linked slow metabolizer status to prolonged exposure to circulating caffeine, reporting modest statistical associations with elevated acute blood pressure reactivity and higher risk of hypertension among heavy coffee drinkers. However, genome-wide association studies show significant heterogeneity across cohorts, indicating that lifestyle factors such as tobacco use, oral contraceptive use, and total dietary intake substantially modify these associations.
Athletic Ergogenics and Mixed Findings
Because caffeine is an established ergogenic aid, sports science researchers have investigated whether rs7625511 genotypes alter exercise performance following caffeine ingestion. Multiple investigations suggest that individuals with the AA genotype experience consistent performance gains in endurance, strength, and cognitive tasks after consuming caffeine. In contrast, several cohorts of CC carriers showed attenuated ergogenic benefits or, in select trials, slight decrements in high-intensity performance. While some studies observed an underrepresentation of CC individuals among elite endurance and team sport athletes, findings across the wider literature remain mixed. Conflicting outcomes highlight that genetic background interacts heavily with caffeine dose, timing, and habitual intake levels.
Interpreting Genetic Data Responsibly
Understanding your rs7625511 genotype provides educational insight into your body's potential rate of caffeine processing, but it is not a clinical diagnostic tool. Genetic variation explains only a fraction of individual caffeine tolerance; liver function, age, pregnancy, microbiome composition, and concurrent medications play profound roles in overall clearance. Readers should not adjust prescriptive drug regimens—such as doses of clozapine, theophylline, or other CYP1A2 substrates—based on direct-to-consumer genetic profiles. Any concerns regarding drug metabolism, adverse pharmaceutical effects, or cardiovascular health should always be evaluated in partnership with a qualified clinician or clinical pharmacogenomics pharmacist.
How common is this variant?
The rs7625511 variant is highly polymorphic globally, with the minor allele frequency typically ranging between 0.30 and 0.45 depending on continental ancestry, making both the A and C alleles common across most studied populations.
Frequently asked questions
Does having the CYP1A2 rs7625511 CC genotype mean I must stop drinking coffee?
No, a CC genotype does not require eliminating coffee or dietary caffeine entirely. It indicates a statistical tendency toward slower hepatic clearance of caffeine compared to carriers of the A allele. Individuals who notice jitters, sleep disturbances, or blood pressure changes may choose to moderate their daily intake after consulting their healthcare provider.
Can rs7625511 testing guide medication doses for prescription drugs?
Direct-to-consumer results for this single SNP are insufficient for clinical prescribing decisions. Although CYP1A2 metabolizes critical pharmaceuticals like clozapine and theophylline, comprehensive clinical guidelines consider multiple variants and patient factors. Always review prescription dosing questions directly with a licensed physician or pharmacist.
Why do some studies on rs7625511 and athletic performance report conflicting results?
Conflicting findings arise because exercise performance is multifactorial and influenced by trial design, participant training status, caffeine dosage, and timing of administration. Furthermore, caffeine binds to adenosine receptors governed by other genes such as ADORA2A, meaning CYP1A2 is only one piece of the metabolic and physiological puzzle.
How do environmental factors like smoking affect this variant's function?
Cigarette smoke contains polycyclic aromatic hydrocarbons that strongly induce the CYP1A2 enzyme via the aryl hydrocarbon receptor pathway, accelerating caffeine metabolism even in slower genotypes. Conversely, oral contraceptives and certain dietary compounds can inhibit the enzyme, showing how lifestyle factors substantially alter genetic expression.
Sources & further reading
Educational information only, last refreshed 9/8/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs7625511?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CYP1A2
This variant in the CYP1A2 gene influences the hepatic metabolism rate of caffeine and is a key marker for individual differences in caffeine clearance.
Intronic marker associated with CYP1A2 enzyme activity and caffeine metabolism rates.
Modulates CYP1A2 inducibility affecting the rate of caffeine metabolism and clearance.
Regulatory variant associated with CYP1A2 enzyme activity, influencing the rate of caffeine metabolism and habitual coffee consumption.
A common variant in the CYP1A2 gene associated with caffeine metabolism rates.
Intronic regulatory polymorphism associated with CYP1A2 inducibility and differences in dietary caffeine metabolism rates.